Skip to main content

Table 1 Clinical trials included in the analysis and fitted parameters for each trial. The study sites are shown in order of increasing transmission intensity, as estimated by the hidden semi-Markov model analysis. Prior EIRs are estimated from the Malaria Atlas Project slide prevalence for each location in the year of the trial [28, 29]

From: The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

Site and referenceCountry, yearPCR correction: molecular markersN (AL/AS-AQ)AS-AQ manufacturer (formulation), target AQ dose*Days of prophylaxis: posterior median (95% CI)EIRFOIPrevalence of pfmdr1 86Y, % (references)Prevalence of pfcrt 76T, % (references)
     ALAS-AQPrior meanPosterior median (95% CI)   
Fougamou [23]Gabon, 2007–2008msp1,msp2,glurp68/68Sanofi-Aventis (FDC Coarsucam) 30 mg/kg11.6 (6.0–16.8)13.1 (7.6–18.6)0.62.3 (1.1–4.2)0.579.5 [30]97.9 [31]
Ndola [23]Zambia, 2007–2009msp1,msp2,glurp69/64Sanofi-Aventis (FDC Coarsucam) 30 mg/kg10.8 (6.0–14.8)16.1 (9.7–25.0)1.24.8 (2.4–8.4)1.0No matching survey20.8 [32]
Pweto [33]Democratic Republic of Congo 2008-2009msp1,msp2,glurp126/129Sanofi-Aventis (AS-AQ Winthrop FDC) 30 mg/kg11.3 (7.8–14.4)17.9 (12.1–25.6)50.09.3 (6.2–13.7)2.0No matching surveyNo matching survey
Pamol [23]Nigeria, 2007–2008msp1,msp2,glurp164/159Sanofi-Aventis (FDC Coarsucam) 30 mg/kg17.9 (12.3–22.5)15.4 (10.3–21.7)22.69.5 (4.7–21.6)2.261.8 [34,35,36]90.1 [37]
Bobo Dioulasso (unpublished‡)Burkina Faso, 2010–2012msp1,msp2373/372Sanofi-Aventis (FDC Coarsucam) 30 mg/kg12.5 (10.6–14.4)16.9 (14.0–19.9)21.517.4 (13.3–23.1)5.918.0 [38, 39]28.5 [38,39,40,41,42]
Gourcy (unpublished‡)Burkina Faso, 2010–2012msp1,msp2112/129Sanofi-Aventis (FDC Coarsucam) 30 mg/kg8.7 (6.2–10.9)17.8 (13.7–22.1)22.923.3 (15.9–33.7)6.518.0 [38, 39]24.8 [39, 41]
Kisumu (unpublished‡)Kenya, 2005msp1,msp2179/178Sanofi and Hoechst Marion Roussel (Loose NFDC) 30 mg/kg18.6 (15.8–21.2)14.2 (10.9–17.6)6.926.5 (18.1–39.6)5.766.6 [43,44,45,46]90.3 [44, 46, 47]
Nimba [48]Liberia, 2008–2009msp1,msp2,glurp127/141Sanofi-Aventis (AS-AQ Winthrop FDC) 30 mg/kg17.9 (15.1–20.6)11.6 (8.8–14.3)18.332.4 (26.1–40.0)8.069.4 [49]93.5 [49]
Sikasso [50]Mali 2005-2007msp1,msp2,CA1236/233Sanofi-Aventis (Coblistered NFDC. Arsucam) 30 mg/kg10.2 (9.0–11.6)18.7 (16.1–21.5)25.237.2 (29.5–46.9)11.335.5 [51]70.2 [32, 51,52,53,54]
Tororo [55]Uganda, 2009–2010msp1,msp2,glurp190/190Sanofi (AS-AQ Winthrop FDC) 30 mg/kg13.3 (11.8–14.6)13.4 (11.7–15.1)23.384.2 (72.9–96.9)16.963.9 [56,57,58]99.6 [56, 58]
Nanoro [23]Burkina Faso, 2007–2008msp1,msp2,glurp257/273Sanofi-Aventis (FDC Coarsucam) 30 mg/kg10.1 (9.2–11.1)17.0 (15.0–19.2)52.291.9 (76.2–111.1)18.931.6 [38, 59]67.0 [32, 38, 42, 59]
Tororo [60]Uganda, 2005msp1,msp2189/195AQ: Parke-David, Pfizer, AS: Sanofi-Aventis (Loose NFDC) 25 mg/kg12.4 (11.1–13.8)10.2 (8.9–11.6)64.6117.1 (98.4–139.8)23.379.4 [56, 61]96.2 [62, 63]
  1. *FDC fixed-dose combination, NFDC non-fixed-dose combination. AS-AQ FDC was from Sanofi. For AL, all trials used the Novartis fixed-dose combination and the same dose regimen
  2. FOI force of infection, estimated mean incidence of patent blood-stage infection in this trial population, given the age distribution and fitted EIR
  3. ‡ Unpublished study references: Bobo Dioulasso, Gourcy: Nikiema F, Zongo I, Some F, Ouedraogo J. Evolution of therapeutic efficacies of artemisinin-based combination therapies (ASAQ and AL) for treatment of uncomplicated falciparum malaria in Burkina Faso during five years of adoption as first-line treatments, unpublished. and Kisumu: Juma EA. Efficacy of co-administered amodiaquine plus artesunate and artemether/lumefantrine for the treatment of uncomplicated falciparum malaria in children less than five years in different epidemiological settings in Kenya, unpublished.